An Anesthetized Cat-and-Rat Cannabis Study Reported Both Active and Null Compound Comparisons

A 1973 study reported cardiovascular and respiratory changes after cannabis extract and THC preparations in anesthetized animals, while CBD and CBN had no observed effects at their tested rat doses. The null comparisons belong to those doses and conditions.

The experimental context was highly specific

The work used intravenous administration, anesthesia and, in cats, a controlled hindquarter perfusion preparation. These conditions differ substantially from ordinary human cannabis use. The historical THC nomenclature and preparation should be retained rather than equating every tested material with a modern product.

Multiple systems were measured

The investigators assessed blood pressure, pulse or heart rate, respiratory rate and vascular responses. The effects were not one generalized cardiovascular score. Autonomic and vascular challenge findings helped explore mechanisms but did not establish one explanation for every response.

Repeated extract exposure produced adaptation

Tolerance developed to selected cardiovascular and respiratory effects in repeatedly treated rats. That result concerns the extract regimen and measured outcomes. An initial null result for another compound does not establish general inactivity, and tolerance does not establish absence of harm.

Interpreting the evidence

The experiment is useful as a historical comparison of compounds and physiological endpoints. It does not predict human responses under different routes or prove that CBD and CBN never affect these systems. Species, anesthesia, preparation and dose are indispensable qualifications.

Related reading: interpreting cannabis tolerance claims.

Research reference

Graham JD; Li DM (1973). Cardiovascular and respiratory effects of cannabis in cat and rat. British journal of pharmacology. PubMed research record.

This analysis draws on the supplied abstract.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

A Pilot Mouse Study Found Declining THC and CBNA Antinociception With Repeated Administration

A 2021 pilot study reported strong initial antinociceptive responses to THC and cannabinolic acid, followed by decreasing responses over subsequent days. The evidence concerns adult male mice and experimental mechanical and thermal tests. The study evaluated two nociceptive domains Mechanical and thermal responses were assessed after systemic intraperitoneal administration. Those…

Spread the love

Read Article: A Pilot Mouse Study Found Declining THC and CBNA Antinociception With Repeated Administration

Short-Term THC–Morphine Treatment Produced Different Receptor-Protein Patterns in Mouse Midbrain and Spinal Cord

A 2001 mouse study found different opioid- and cannabinoid-receptor protein patterns across midbrain and spinal cord after short-term THC–morphine treatment. A statement about total receptor change would obscure those tissue-specific comparisons. The comparison included separate treatment groups Investigators assessed THC, morphine and their combination using Western blot measurements. Opioid-receptor protein…

Spread the love

Read Article: Short-Term THC–Morphine Treatment Produced Different Receptor-Protein Patterns in Mouse Midbrain and Spinal Cord

A THC Kinase Study Distinguished Reversing Tolerance From Reducing the Initial Drug Effect

A 2003 study found that selected kinase inhibitors reversed THC antinociceptive tolerance while others did not. One higher-dose intervention reduced THC's acute antinociceptive effect, illustrating a different outcome from reversing tolerance. The panel included useful negatives The study tested interventions directed at several kinases. Some did not affect tolerance under…

Spread the love

Read Article: A THC Kinase Study Distinguished Reversing Tolerance From Reducing the Initial Drug Effect

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us